Document is current
Any future updates will be listed below
-
Authors
Park, Hong-Su http://orcid.org/0000-0002-8423-2188
Matsuoka, Yumiko
Luongo, Cindy
Yang, Lijuan
Santos, Celia
Liu, Xueqiao
Ahlers, Laura R. H.
Moore, Ian N.
Afroz, Sharmin
Johnson, Reed F.
Lafont, Bernard A. P. http://orcid.org/0000-0003-2140-6205
Dorward, David W.
Fischer, Elizabeth R.
Martens, Craig
Samal, Siba K.
Munir, Shirin
Buchholz, Ursula J. http://orcid.org/0000-0002-2329-3198
Le Nouën, Cyril http://orcid.org/0000-0002-5719-4112
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases
University of Maryland
- License Information
-
More Information
Article History
Received: 21 December 2021
Accepted: 11 May 2022
First Online: 28 June 2022
Competing interests
: H.-S.P., C.L., S.M., U.J.B., and C.L.N. are inventors on the provisional patent application number 63/280,884, entitled “Expression of the spike glycoprotein of SARS-CoV-2 from avian paramyxovirus type 3 (APMV3)”, filed by the United States of America, Department of Health and Human Services.
